Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support.

N/ACompletedNCT04512027

Composite Interceptive Med Science10 enrolled

Overview

A randomised controlled trial of open label Prolectin-M; a (1-6)-alpha-D-Mannopyranose among patients with RT PCR positive COVID-19 patients.

SarsCoV2 has infected over 20 million people worldwide. The virus has a unique protein structure enabling it to rapidly infect and spread among the population. COVID19 is a global health emergency and has affected lives of all people irrespective of being infected. There are no proven therapies and a vaccine is yet to be approved for wide public usage. Our study aims to test a hypothesis of physically blocking the spike protein from infecting the human cells, thus promoting its rapid excretion from the infected person. We will randomise 10 subjects in this proof of concept trial and test the hypothesis by measuring the effect of Prolectin-M; a (1-6)-alpha-D-Mannopyranose in reducing the viral copy numbers over 5 days of treatment. The absolute copy numbers will be measured on digital droplet PCR developed by BioRad. A fall in copy numbers by 2-fold from baseline will be considered a positive treatment effect in this population. All standard care measures currently being practiced for these patients will be continued.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

COVID-19

Interventions

Prolectin-M; a (1-6)-alpha-D-Mannopyranose classOTHER

A treatment to decrease viral load, detected through digital droplet PCR, in mild to moderate cases of RT-PCR positive COVID-19

Standard of CareOTHER

Currently approved standard of care for patients without symptoms requiring hospitalisation will be provided to all.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Symptomatic and laboratory-confirmed diagnosis of COVID-19. * Age ≥18 years and ≤45 years, male and non-pregnant female * Identified within 72 hours of testing positive on RT PCR. * Able to give informed consent to stay in institutional care and undergo 3 times collection of throat and nasal swabs over 7-day period; Day 1, Day 3 and Day 5 since randomization. Exclusion Criteria: * Oxygen saturation at admission ≤96%. * High temperature ≥100 deg F (≥37.5 deg C) not controlled on oral doses of acetaminophen. * Known history of diabetes on oral medications or insulin. * IL-6 levels ≥ 3times of laboratory reference range and / or significantly elevated levels of CRP, serum ferritin or d-dimer. * Lymphocyte / monocyte ratio ≤3 or neutrophil / lymphocyte ratio ≥5 or platelet count ≤150,000 cells per microliter * On any chronic medications for more than 4 weeks before randomization or active malignancy or having any co-morbidity that increases risk of rapid disease progression. * Previously tested positive and recovered from COVID-19

Locations (1)

Mazumdar Shaw Medical Centre

Bangalore, Karnataka, India

Outcomes

Primary Outcomes

SarsCoV2 viral copy number

Change in absolute viral copy number

Time frame: 7 days from randomisation

Secondary Outcomes

b. Disease progression will be measured on a 7-point scale at 28 days. A 2-point change will be considered disease progression.

7-point severity score (ordinal scale): 1. Not hospitalized, no limitations on activities 2. Not hospitalized, limitation on activities; 3. Hospitalized, not requiring supplemental oxygen; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, on non-invasive ventilation or high flow oxygen devices; 6. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 7. Death

Time frame: 28 days from randomisation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.